Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics Announces Full Commercial Launch and Nationwide Availability of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension)
Recently approved, non-opioid therapy now available for the management of osteoarthritis knee pain Launch of ZILRETTA commences with full complement of field sales personnel deployed across the U.S. BURLINGTON, Mass., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc.
View HTML
Toggle Summary Flexion Therapeutics Named Top Place to Work for 2017 by The​ ​Boston​ ​Globe​
Annual survey recognizes and honors the best employers in Massachusetts BURLINGTON, Mass., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has been named one of the Top Places to Work in Massachusetts in the 10th annual employee-based survey
View HTML
Toggle Summary Flexion Therapeutics Reports Third-Quarter 2017 Financial Results and Recent Business Highlights
Zilretta TM (triamcinolone acetonide extended-release injectable suspension) received FDA approval for the management of osteoarthritis (OA) knee pain on October 6, 2017 Product was made commercially available on October 23, 2017, with full launch planned for late November Recent equity offering
View HTML
Toggle Summary Flexion Therapeutics Highlights Two Clinical Data Presentations at the 2017 American College of Rheumatology Annual Meeting
In a pooled analysis, Zilretta TM (triamcinolone acetonide extended-release injectable suspension) demonstrated sustained clinical improvement in knee osteoarthritis (OA) pain and function versus placebo, irrespective of baseline clinical inflammation In an expansion of a recently published
View HTML
Toggle Summary Flexion Therapeutics to Report Third-Quarter 2017 Financial Results on November 6, 2017
BURLINGTON, Mass., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to provide an update on business operations and report its third-quarter 2017 financial results on Monday, November 6, 2017, at 4:30 p.m. ET.
View HTML
Toggle Summary Flexion Therapeutics Announces Pricing of Public Offering of Common Stock
BURLINGTON, Mass., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of an underwritten public offering of 4,800,000 shares of its common stock at a price to the public of $25.50 per share.  The gross proceeds from this offering are expected to
View HTML
Toggle Summary Flexion Therapeutics Announces Proposed Public Offering of Common Stock
BURLINGTON, Mass., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell 4,000,000 shares of its common stock.
View HTML
Toggle Summary Flexion Therapeutics to Hold Conference Call at 8:00 a.m. ET to Discuss Recent FDA Approval of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension)
-  Management to review product label and highlight launch plans BURLINGTON, Mass., Oct. 9, 2017 /PRNewswire/ -- Flexion Therapeutics, Inc. (Nasdaq: FLXN) will hold a conference call today, Monday, October 9, 2017, at 8:00 a.m. ET to discuss the recent U.S.
View HTML
Toggle Summary Flexion Therapeutics Announces FDA Approval of Zilretta™ (triamcinolone acetonide extended-release injectable suspension) for Osteoarthritis (OA) Knee Pain
  Innovative, non-opioid, intra-articular therapy, proven to deliver meaningful analgesia over 12 weeks in patients with moderate to severe OA knee pain   Product label also includes positive data from type 2 diabetes study   Commercial supply expected to be available by late October following
View HTML
Toggle Summary Flexion Therapeutics to Present Data on Zilretta™ (FX006) at PAINWeek 2017
Analysis shows statistically significant reduction in the use of rescue medications following treatment with Zilretta
View HTML